ADCT
ADC Therapeutics SA
NYSE · Healthcare · Biotechnology · CH
$1.44
+3.23%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 2.04x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -0.81x
- Price / sales
- 2.33x
- Price / cash flow
- -1.80x
Enterprise value
- Enterprise value
- $381.8M
- EV / sales
- 4.85x
- EV / EBITDA
- -4.36x
- EV / EBIT
- -3.85x
- Market cap
- $183.8M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026